Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josh J Carlson

Showing results (21-30 of 106) with videos related to

Pageof 11
Sort By:
Pharmacoeconomics|July 28, 2020
Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut SyndromeEdward E Neuberger, Josh J Carlson, David L Veenstra
Journal of Geriatric Oncology|November 27, 2022
Can we predict trial failure among older adult-specific clinical trials using trial-level factors?Woojung Lee, Anirban Basu, Josh J Carlson, et al.
Journal of Medical Economics|December 12, 2012
Comparative effectiveness research in the United States: a progress reportSean D Sullivan, Josh J Carlson, Ryan N Hansen
The Oncologist|October 21, 2015
Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate CancerJoshua A Roth, Scott D Ramsey, Josh J Carlson
Contemporary Clinical Trials|March 3, 2023
How does cumulative evidence from older adult-specific trials influence clinical practice? A difference-in-differences analysis in early-stage breast cancerWoojung Lee, Anirban Basu, Josh J Carlson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 8, 2024
Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis FrameworkBoshen Jiao, Josh J Carlson, Louis P Garrison, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 2, 2020
Exploring Medication Adherence with P2Y<sub>12</sub> Inhibitors Using Conditional and Unconditional Quantile Regression ApproachesKangho Suh, Anirban Basu, Josh J Carlson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2019
Defining and Managing High-Priced Cures: Healthcare Payers' OpinionsKai Yeung, Kangho Suh, Louis P Garrison, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritisJosh J Carlson, Sarika Ogale, Fred Dejonckheere, et al.
Journal of Medical Economics|February 4, 2011
Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancerJosh J Carlson, William B Wong, David L Veenstra, et al.
Pageof 11

Showing results (21-30 of 106) with videos related to

Sort By:
Pageof 11
Pharmacoeconomics|July 28, 2020
Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut SyndromeEdward E Neuberger, Josh J Carlson, David L Veenstra
Journal of Geriatric Oncology|November 27, 2022
Can we predict trial failure among older adult-specific clinical trials using trial-level factors?Woojung Lee, Anirban Basu, Josh J Carlson, et al.
Journal of Medical Economics|December 12, 2012
Comparative effectiveness research in the United States: a progress reportSean D Sullivan, Josh J Carlson, Ryan N Hansen
The Oncologist|October 21, 2015
Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate CancerJoshua A Roth, Scott D Ramsey, Josh J Carlson
Contemporary Clinical Trials|March 3, 2023
How does cumulative evidence from older adult-specific trials influence clinical practice? A difference-in-differences analysis in early-stage breast cancerWoojung Lee, Anirban Basu, Josh J Carlson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 8, 2024
Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis FrameworkBoshen Jiao, Josh J Carlson, Louis P Garrison, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 2, 2020
Exploring Medication Adherence with P2Y<sub>12</sub> Inhibitors Using Conditional and Unconditional Quantile Regression ApproachesKangho Suh, Anirban Basu, Josh J Carlson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2019
Defining and Managing High-Priced Cures: Healthcare Payers' OpinionsKai Yeung, Kangho Suh, Louis P Garrison, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritisJosh J Carlson, Sarika Ogale, Fred Dejonckheere, et al.
Journal of Medical Economics|February 4, 2011
Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancerJosh J Carlson, William B Wong, David L Veenstra, et al.
Pageof 11